IMVARIA Labs Expands AI Diagnostic Testing with InVision Precision Cardiac Amyloid

SUNNYVALE, CA, UNITED STATES, October 5, 2026 /CourierPR/ -- IMVARIA Labs, a health tech diagnostic company, has expanded its AI diagnostic testing services by partnering with InVision Medical Technology to offer the InVision Precision Cardiac Amyloid (PCA) algorithm through its AI Lab. This move aims to enhance access to a tool that helps clinicians detect cardiac amyloidosis, a condition often missed or diagnosed late.

InVision Medical Technology, an AI echocardiography company, developed the PCA algorithm, which received FDA 510(k) clearance in May 2025 for adults aged 65 and older. The algorithm runs on routine echocardiograms and alerts the interpreting physician when a patient should be referred for confirmatory testing. IMVARIA’s AI Lab, which has extensive experience in delivering AI diagnostic testing, will now offer this algorithm to clinicians who do not run the software within their own imaging systems.

Cardiac amyloidosis remains widely underdiagnosed, despite the availability of approved therapies for transthyretin amyloidosis cardiomyopathy (ATTR-CM) that have been shown to reduce mortality and cardiovascular hospitalization and to improve quality of life. Earlier diagnosis gives patients more time to benefit from treatment.

IMVARIA, founded in 2019 by physician-engineers from Google and Stanford University, operates its AI Lab with automated, machine-learning algorithm technology to transform clinical decision-making into data science. The company currently provides Fibresolve, the first FDA-cleared AI adjunctive diagnostic service for lung fibrosis, and ScreenDx, the first FDA-cleared AI technology authorized to assess findings compatible with interstitial lung disease.

IMVARIA’s AI Lab operates as an independent diagnostic testing facility and accepts cases on the order of a treating physician. This partnership with InVision Medical Technology is expected to streamline the diagnostic process for clinicians and improve patient outcomes by ensuring that suspicious cases of cardiac amyloidosis are not overlooked.

InVision Medical Technology is an AI technology company focused on improving the precision and accuracy of cardiovascular imaging. The company's software tools enhance the performance of echocardiography, the most common and easily accessible cardiac imaging modality.